Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASAH1 | Q13510 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | ACER2 | Q5QJU3 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | CERT1 | Q9Y5P4 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10832852 | 0.85 | ASAH1 (0.62) | ASAH1ALDH1A1ACER2CERT1NPSR1 | |
| SCHEMBL13271749 | 0.84 | ASAH1 (0.47) | ASAH1ALDH1A1ACER2CERT1NPSR1 | |
| SCHEMBL13033201 | 0.82 | HPGD (0.49) | ALDH1A1HDAC6HDAC3HDAC4HDAC1 | |
| SCHEMBL13616391 | 0.80 | GPR139 (0.44) | ALDH1A1MAPTTACR3 | |
| SCHEMBL13032995 | 0.79 | HTR2A (0.44) | HTR2AHRH1TACR1TACR3 | |
| SCHEMBL2628428 | 0.78 | HDAC1 (0.60) | ALDH1A1HDAC6HDAC3HDAC4HDAC1 | |
| SCHEMBL13032996 | 0.77 | HTR2A (0.49) | HTR2AHRH1TACR1TACR3 | |
| SCHEMBL2628432 | 0.77 | HTR2A (0.53) | HTR2AHRH1TACR1TACR3 | |
| SCHEMBL15443129 | 0.77 | LMNA (0.51) | ALDH1A1NPSR1MAPTHPGDGAA | |
| SCHEMBL16316559 | 0.77 | TACR3 (0.44) | ALDH1A1MAPTHPGDTACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3210998-A1 | METASTIN DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2017-08-30 | — | — | EP | disclosed |
| US-9175037-B2 | Neuromedin U derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-03 | — | — | US | disclosed |
| US-9175037-B2 | Neuromedin U derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-03 | — | — | US | disclosed |
| US-20120094899-A1 | NEUROMEDIN U DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120094899-A1 | NEUROMEDIN U DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20110212890-A1 | METASTIN DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-01 | — | — | US | disclosed |
| US-20110212890-A1 | METASTIN DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-01 | — | — | US | disclosed |
| EP-2314609-A1 | METASTIN DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-04-27 | — | — | EP | disclosed |
| US-20100286035-A1 | NEUROMEDIN U DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-11 | — | — | US | disclosed |
| US-20100286035-A1 | NEUROMEDIN U DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-11 | — | — | US | disclosed |
| EP-2206721-A1 | NEUROMEDIN U DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2010-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286035-A1 | NEUROMEDIN U DERIVATIVE | NMUR1, NMUR2, NMBR | ASAH1 3118/4885ALDH1A1 3894/4885ACER2 3826/4885 |
| US-20120094899-A1 | NEUROMEDIN U DERIVATIVE | NMUR1, NMUR2, NMBR | ASAH1 3085/4885ALDH1A1 3304/4885ACER2 3906/4885 |
| US-20110212890-A1 | METASTIN DERIVATIVE AND USE THEREOF | GNRHR, SHBG, LHCGR | ASAH1 2867/4885ALDH1A1 4055/4885ACER2 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.